Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks…